This trial is designed to test the safety, immunogenicity, and clinical activity of autologous peripheral blood dendritic cells (DCs) pulsed with tumor-derived idiotype protein in patients who have undergone high dose therapy and stem cell rescue for B cell lymphomas and multiple myeloma. The long-term goal of this study is to develop a vaccine therapy which will induce a clinically effective immune responses. The vaccine is produced on a custom basis from each patient's tumor cells and peripheral blood dendritic cells. In pilot studies in lymphoma, cellular immune responses and tumor regressions have been observed.
Showing the most recent 10 out of 589 publications